Elevated AKIP1 expression is associated with tumor invasion, shorter survival time and decreased chemosensitivity in endometrial carcinoma
A-kinase-interacting protein 1 (AKIP1), as a recently discovered oncoprotein, promotes cell malignant behaviors in gynecological malignancies. To the best of our knowledge, no study reports its clinical value in patients with endometrial carcinoma. The present study aimed to explore the association...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2022-08, Vol.24 (2), p.1, Article 268 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 1 |
| container_title | Oncology letters |
| container_volume | 24 |
| creator | Li, Aili Li, Aijing Gao, Xiangpeng Zhang, Tongyan Ma, Zhiling Xiao, Yalin Zhao, Fei |
| description | A-kinase-interacting protein 1 (AKIP1), as a recently discovered oncoprotein, promotes cell malignant behaviors in gynecological malignancies. To the best of our knowledge, no study reports its clinical value in patients with endometrial carcinoma. The present study aimed to explore the association between AKIP1 expression and clinical features and survival in patients with endometrial carcinoma, and to assess the effect of AKIP1 knockdown on the regulation of chemosensitivity in vitro. The tumor and adjacent tissue specimens from 101 patients with endometrial carcinoma were retrieved for AKIP1 protein expression analysis using an immunohistochemistry (IHC) assay. Meanwhile, specimens from 54 patients with endometrial carcinoma were analyzed for AKIP1 mRNA expression using reverse transcription-quantitative PCR. Furthermore, an in vitro experiment was conducted in the Ishikawa cell line to determine the effect of AKIP1 modification on the chemosensitivity of cisplatin and paclitaxel. AKIP1 IHC score (P |
| doi_str_mv | 10.3892/ol.2022.13388 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9247666</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714306372</galeid><sourcerecordid>A714306372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-c8b7f053beee8b1c2b17e83ebeb12de39b6d6192331dbe597717286da21cf14b3</originalsourceid><addsrcrecordid>eNptkk9rFTEUxQdRbKldug8IrpznJJlJMhvhUaoWC3Wh65A_dzopM8kzyUztV_BTm9eW0gdNFgn3_s4hl5yqeo-bDRU9-RymDWkI2WBKhXhVHWPekxo3grx-uvP2qDpN6aYpq2NYCPa2OqIdF0T0_Lj6dz7BqjJYtP1x8RMj-LuLkJILHrmEVErBuPv2rcsjysscInJ-VXviE0pjiBkiSktc3aomlN0MSHmLLJgIKhWhGWEOCXxy2a0u3xU5Am_DDDm6IjEqGufDrN5VbwY1JTh9PE-q31_Pf519ry-vvl2cbS9r07Ys10ZoPjQd1QAgNDZEYw6CggaNiQXaa2YZ7gml2Groes4xJ4JZRbAZcKvpSfXlwXe36BmsAZ-jmuQuulnFOxmUk4cd70Z5HVbZk5YzxorBh0eDGP4skLK8CUv05c2SsJ53XUPJM-paTSCdH0IxM7NLRm45bmnDKCeF2rxAlW1hdiZ4GFypHwg-PhOMoKY8pjAtuXxIOgTrB9DEkFKE4WlC3Mh9emSY5D498j499D_kbrgk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2697550326</pqid></control><display><type>article</type><title>Elevated AKIP1 expression is associated with tumor invasion, shorter survival time and decreased chemosensitivity in endometrial carcinoma</title><source>Spandidos Publications Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Li, Aili ; Li, Aijing ; Gao, Xiangpeng ; Zhang, Tongyan ; Ma, Zhiling ; Xiao, Yalin ; Zhao, Fei</creator><creatorcontrib>Li, Aili ; Li, Aijing ; Gao, Xiangpeng ; Zhang, Tongyan ; Ma, Zhiling ; Xiao, Yalin ; Zhao, Fei</creatorcontrib><description>A-kinase-interacting protein 1 (AKIP1), as a recently discovered oncoprotein, promotes cell malignant behaviors in gynecological malignancies. To the best of our knowledge, no study reports its clinical value in patients with endometrial carcinoma. The present study aimed to explore the association between AKIP1 expression and clinical features and survival in patients with endometrial carcinoma, and to assess the effect of AKIP1 knockdown on the regulation of chemosensitivity in vitro. The tumor and adjacent tissue specimens from 101 patients with endometrial carcinoma were retrieved for AKIP1 protein expression analysis using an immunohistochemistry (IHC) assay. Meanwhile, specimens from 54 patients with endometrial carcinoma were analyzed for AKIP1 mRNA expression using reverse transcription-quantitative PCR. Furthermore, an in vitro experiment was conducted in the Ishikawa cell line to determine the effect of AKIP1 modification on the chemosensitivity of cisplatin and paclitaxel. AKIP1 IHC score (P<0.001) and mRNA expression levels (P<0.001) were increased in tumor tissues compared with those in adjacent tissues. Moreover, increased AKIP1 IHC score was associated with lymphovascular invasion (P=0.007), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P=0.002) and shorter overall survival (OS) time (P=0.035) in the patients with endometrial carcinoma. Meanwhile, upregulated AKIP1 mRNA expression levels were associated with lymphovascular invasion (P=0.020) and advanced FIGO stage (P=0.027) in the patients with endometrial carcinoma. Multivariate Cox regression showed that tumor AKIP1 protein expression (high vs. low) independently predicted a shorter OS time (P=0.036). Silencing of AKIP1 decreased Ishikawa cell viability when treated with 5, 10, 20 and 40 [micro]M cisplatin (all P<0.05) and decreased the half maximal inhibitory concentration value of cisplatin (P=0.003), whereas its effect on paclitaxel chemosensitivity was less obvious. Overall, elevated AKIP1 expression was associated with tumor invasion, shorter survival time and decreased chemosensitivity in endometrial carcinoma. Key words: endometrial carcinoma, AKIP1, survival, clinicopathological features, chemosensitivity</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2022.13388</identifier><identifier>PMID: 35782897</identifier><language>eng</language><publisher>Athens: Spandidos Publications</publisher><subject>Analysis ; Antibodies ; Biomarkers ; Cancer ; Cancer therapies ; Carcinoma ; Care and treatment ; Cervical cancer ; Diagnosis ; Endometrial cancer ; Gynecology ; Immunohistochemistry ; Kinases ; Medical prognosis ; Medical research ; Medicine, Experimental ; Oncology ; Protein expression ; Proteins ; RNA ; Scientific equipment and supplies industry ; Survival analysis</subject><ispartof>Oncology letters, 2022-08, Vol.24 (2), p.1, Article 268</ispartof><rights>COPYRIGHT 2022 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2022</rights><rights>Copyright: © Li et al. 2022</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c446t-c8b7f053beee8b1c2b17e83ebeb12de39b6d6192331dbe597717286da21cf14b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247666/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247666/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Li, Aili</creatorcontrib><creatorcontrib>Li, Aijing</creatorcontrib><creatorcontrib>Gao, Xiangpeng</creatorcontrib><creatorcontrib>Zhang, Tongyan</creatorcontrib><creatorcontrib>Ma, Zhiling</creatorcontrib><creatorcontrib>Xiao, Yalin</creatorcontrib><creatorcontrib>Zhao, Fei</creatorcontrib><title>Elevated AKIP1 expression is associated with tumor invasion, shorter survival time and decreased chemosensitivity in endometrial carcinoma</title><title>Oncology letters</title><description>A-kinase-interacting protein 1 (AKIP1), as a recently discovered oncoprotein, promotes cell malignant behaviors in gynecological malignancies. To the best of our knowledge, no study reports its clinical value in patients with endometrial carcinoma. The present study aimed to explore the association between AKIP1 expression and clinical features and survival in patients with endometrial carcinoma, and to assess the effect of AKIP1 knockdown on the regulation of chemosensitivity in vitro. The tumor and adjacent tissue specimens from 101 patients with endometrial carcinoma were retrieved for AKIP1 protein expression analysis using an immunohistochemistry (IHC) assay. Meanwhile, specimens from 54 patients with endometrial carcinoma were analyzed for AKIP1 mRNA expression using reverse transcription-quantitative PCR. Furthermore, an in vitro experiment was conducted in the Ishikawa cell line to determine the effect of AKIP1 modification on the chemosensitivity of cisplatin and paclitaxel. AKIP1 IHC score (P<0.001) and mRNA expression levels (P<0.001) were increased in tumor tissues compared with those in adjacent tissues. Moreover, increased AKIP1 IHC score was associated with lymphovascular invasion (P=0.007), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P=0.002) and shorter overall survival (OS) time (P=0.035) in the patients with endometrial carcinoma. Meanwhile, upregulated AKIP1 mRNA expression levels were associated with lymphovascular invasion (P=0.020) and advanced FIGO stage (P=0.027) in the patients with endometrial carcinoma. Multivariate Cox regression showed that tumor AKIP1 protein expression (high vs. low) independently predicted a shorter OS time (P=0.036). Silencing of AKIP1 decreased Ishikawa cell viability when treated with 5, 10, 20 and 40 [micro]M cisplatin (all P<0.05) and decreased the half maximal inhibitory concentration value of cisplatin (P=0.003), whereas its effect on paclitaxel chemosensitivity was less obvious. Overall, elevated AKIP1 expression was associated with tumor invasion, shorter survival time and decreased chemosensitivity in endometrial carcinoma. Key words: endometrial carcinoma, AKIP1, survival, clinicopathological features, chemosensitivity</description><subject>Analysis</subject><subject>Antibodies</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma</subject><subject>Care and treatment</subject><subject>Cervical cancer</subject><subject>Diagnosis</subject><subject>Endometrial cancer</subject><subject>Gynecology</subject><subject>Immunohistochemistry</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Oncology</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>RNA</subject><subject>Scientific equipment and supplies industry</subject><subject>Survival analysis</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkk9rFTEUxQdRbKldug8IrpznJJlJMhvhUaoWC3Wh65A_dzopM8kzyUztV_BTm9eW0gdNFgn3_s4hl5yqeo-bDRU9-RymDWkI2WBKhXhVHWPekxo3grx-uvP2qDpN6aYpq2NYCPa2OqIdF0T0_Lj6dz7BqjJYtP1x8RMj-LuLkJILHrmEVErBuPv2rcsjysscInJ-VXviE0pjiBkiSktc3aomlN0MSHmLLJgIKhWhGWEOCXxy2a0u3xU5Am_DDDm6IjEqGufDrN5VbwY1JTh9PE-q31_Pf519ry-vvl2cbS9r07Ys10ZoPjQd1QAgNDZEYw6CggaNiQXaa2YZ7gml2Groes4xJ4JZRbAZcKvpSfXlwXe36BmsAZ-jmuQuulnFOxmUk4cd70Z5HVbZk5YzxorBh0eDGP4skLK8CUv05c2SsJ53XUPJM-paTSCdH0IxM7NLRm45bmnDKCeF2rxAlW1hdiZ4GFypHwg-PhOMoKY8pjAtuXxIOgTrB9DEkFKE4WlC3Mh9emSY5D498j499D_kbrgk</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Li, Aili</creator><creator>Li, Aijing</creator><creator>Gao, Xiangpeng</creator><creator>Zhang, Tongyan</creator><creator>Ma, Zhiling</creator><creator>Xiao, Yalin</creator><creator>Zhao, Fei</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20220801</creationdate><title>Elevated AKIP1 expression is associated with tumor invasion, shorter survival time and decreased chemosensitivity in endometrial carcinoma</title><author>Li, Aili ; Li, Aijing ; Gao, Xiangpeng ; Zhang, Tongyan ; Ma, Zhiling ; Xiao, Yalin ; Zhao, Fei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-c8b7f053beee8b1c2b17e83ebeb12de39b6d6192331dbe597717286da21cf14b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Antibodies</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma</topic><topic>Care and treatment</topic><topic>Cervical cancer</topic><topic>Diagnosis</topic><topic>Endometrial cancer</topic><topic>Gynecology</topic><topic>Immunohistochemistry</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Oncology</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>RNA</topic><topic>Scientific equipment and supplies industry</topic><topic>Survival analysis</topic><toplevel>online_resources</toplevel><creatorcontrib>Li, Aili</creatorcontrib><creatorcontrib>Li, Aijing</creatorcontrib><creatorcontrib>Gao, Xiangpeng</creatorcontrib><creatorcontrib>Zhang, Tongyan</creatorcontrib><creatorcontrib>Ma, Zhiling</creatorcontrib><creatorcontrib>Xiao, Yalin</creatorcontrib><creatorcontrib>Zhao, Fei</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Aili</au><au>Li, Aijing</au><au>Gao, Xiangpeng</au><au>Zhang, Tongyan</au><au>Ma, Zhiling</au><au>Xiao, Yalin</au><au>Zhao, Fei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated AKIP1 expression is associated with tumor invasion, shorter survival time and decreased chemosensitivity in endometrial carcinoma</atitle><jtitle>Oncology letters</jtitle><date>2022-08-01</date><risdate>2022</risdate><volume>24</volume><issue>2</issue><spage>1</spage><pages>1-</pages><artnum>268</artnum><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>A-kinase-interacting protein 1 (AKIP1), as a recently discovered oncoprotein, promotes cell malignant behaviors in gynecological malignancies. To the best of our knowledge, no study reports its clinical value in patients with endometrial carcinoma. The present study aimed to explore the association between AKIP1 expression and clinical features and survival in patients with endometrial carcinoma, and to assess the effect of AKIP1 knockdown on the regulation of chemosensitivity in vitro. The tumor and adjacent tissue specimens from 101 patients with endometrial carcinoma were retrieved for AKIP1 protein expression analysis using an immunohistochemistry (IHC) assay. Meanwhile, specimens from 54 patients with endometrial carcinoma were analyzed for AKIP1 mRNA expression using reverse transcription-quantitative PCR. Furthermore, an in vitro experiment was conducted in the Ishikawa cell line to determine the effect of AKIP1 modification on the chemosensitivity of cisplatin and paclitaxel. AKIP1 IHC score (P<0.001) and mRNA expression levels (P<0.001) were increased in tumor tissues compared with those in adjacent tissues. Moreover, increased AKIP1 IHC score was associated with lymphovascular invasion (P=0.007), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P=0.002) and shorter overall survival (OS) time (P=0.035) in the patients with endometrial carcinoma. Meanwhile, upregulated AKIP1 mRNA expression levels were associated with lymphovascular invasion (P=0.020) and advanced FIGO stage (P=0.027) in the patients with endometrial carcinoma. Multivariate Cox regression showed that tumor AKIP1 protein expression (high vs. low) independently predicted a shorter OS time (P=0.036). Silencing of AKIP1 decreased Ishikawa cell viability when treated with 5, 10, 20 and 40 [micro]M cisplatin (all P<0.05) and decreased the half maximal inhibitory concentration value of cisplatin (P=0.003), whereas its effect on paclitaxel chemosensitivity was less obvious. Overall, elevated AKIP1 expression was associated with tumor invasion, shorter survival time and decreased chemosensitivity in endometrial carcinoma. Key words: endometrial carcinoma, AKIP1, survival, clinicopathological features, chemosensitivity</abstract><cop>Athens</cop><pub>Spandidos Publications</pub><pmid>35782897</pmid><doi>10.3892/ol.2022.13388</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2022-08, Vol.24 (2), p.1, Article 268 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9247666 |
| source | Spandidos Publications Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Analysis Antibodies Biomarkers Cancer Cancer therapies Carcinoma Care and treatment Cervical cancer Diagnosis Endometrial cancer Gynecology Immunohistochemistry Kinases Medical prognosis Medical research Medicine, Experimental Oncology Protein expression Proteins RNA Scientific equipment and supplies industry Survival analysis |
| title | Elevated AKIP1 expression is associated with tumor invasion, shorter survival time and decreased chemosensitivity in endometrial carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T06%3A44%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20AKIP1%20expression%20is%20associated%20with%20tumor%20invasion,%20shorter%20survival%20time%20and%20decreased%20chemosensitivity%20in%20endometrial%20carcinoma&rft.jtitle=Oncology%20letters&rft.au=Li,%20Aili&rft.date=2022-08-01&rft.volume=24&rft.issue=2&rft.spage=1&rft.pages=1-&rft.artnum=268&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2022.13388&rft_dat=%3Cgale_pubme%3EA714306372%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2697550326&rft_id=info:pmid/35782897&rft_galeid=A714306372&rfr_iscdi=true |